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CHRONIC LIVER ALLOGRAFT REJECTION IN A POPULATION 
TREATED PRIMARILY WITH TACROLIMUS AS BASELINE 
IMMUNOSUPPRESSION 
LONG-TERM FOLLOW-UP AND EVALUATION OF FEATURES FOR HISTOPATHOLOGICAL STAGING 1 
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Background. Predisposing factors, long-term occur-
rence, and histopathological changes associated with 
recovery or progression to allograft failure from 
chronic rejection (CR) were studied in adult patients 
treated primarily with tacrolimus. 
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Methods. CR cases were identified using stringent 
criteria applied to a retrospective review of comput-
erized clinicopathological data and slides. 
Results. After 1973 days median follow-up, 35 (3.3%) 
of 1049 primary liver allograft recipients first devel-
oped CR between 16 and 2532 (median 242) days. The 
most significant risk factors for CR were the number 
(P<O.OOl) and histological severity (P<0.005) of acute 
rejection episodes and donor age >40 years (P<0.03)_ 
Other demographic and matching parameters were 
not associated with CR in this cohort. Ten patients 
died with, but not of, CR. Eight required retransplan-
tation because of CR at a median of 268 days. Ten 
resolved either histologically or by normalization of 
liver injury tests over a median of 548 days. CR per-
sisted for 340 to 2116 days in the remaining seven 
patients. More extensive bile duct los8 (P<O.Ol), small 
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arterial loss (P<O.03), foam cell clusters (P<O.OI) and 
higher total bilirubin (P<O.02) and aspartate amino-
transferase (P<O.03) were associated with allograft 
failure from CR. 
Conclusions. Early chronic liver allograft rejection 
is potentially reversible and a combination of histolog-
ical, clinical, and laboratory data can be used to stage 
CR. Unique immunological and regenerative proper-
ties of liver allografts, which lead to a low incidence 
and reversibility of early CR, can provide insights into 
transplantation biology. 
Chronic rejection (Cm is the major obstacle to morbidity-
free long-term survival of mostly all vascularized solid organ 
allograft recipients. Liver allografts are an exception in that 
the incidence of CR at 5 years after transplantation has 
steadily decreased from 20 to 40% in the early 1980s to less 
than 5% in current recipients (1, 2). The unique immunolog-
ical properties of the liver as an allograft (3, 4), and better 
recognition and control of acute rejection and the early 
phases ofCR with tacrolimus (5-8), are thought to be respon-
sible for the recent decline in the number of cases (3, 5, 8 -1 0). 
Furthermore, the liver is the only organ in humans in which 
CR is potentially reversible (5, 7, 8, 11-13), and a hepatic 
allograft can protect other organs from the same donor from 
CR (14). 
Until recently, no general agreement existed regarding the 
histological definition of CR in the liver. Some groups recog-
nized early and late stages of CR, the former being recog-
nized by bile duct atrophy/pyknosis affecting a majority of 
the ducts, with or without <50% ductopenia (8, 11, 13, 15). In 
other centers, CR was diagnosed only when bile ducts were 
absent in more than 50% of portal tracts or obliterative 
arteriopathy was seen (16-18). Since obliterative arteriopa-
thy usually affects medium-sized muscular arteries in the 
liver hilum, which are rarely sampled in needle biopsies, 
significant weight was placed on the 50% ductopenia (16-18). 
A recent study of CR in a large multicenter primarily 
cyclosporine-treated patient cohort that included children, 
clarified the issue by showing that early CR was a distinct 
clinicopathological syndrome that could be reliably diagnosed 
using the above criteria (15). An in-depth study of that pop-
ulation showed that the early stage is more frequently re-
versible (19), consistent with previous studies (5, 7,8,11-13). 
This is likely due to less extensive bile duct loss, lack of 
significant fibrosis, and minimal vascular abnormalities in 
the early stage of CR, combined with the ability of hepato-
cytes and biliary epithelial cells to regenerate. In contrast, 
the late stage of CR, which is less commonly reversible, 
shows evidence of more extensive fibrosis, widespread bile 
duct loss, and obliterative arteriopathy, some of which may 
be irreversible (5, 8, 13,20). 
The current study was conducted to firstly investigate pre-
disposing factors and the long-term occurrence of CR in an 
adult patient population receiving tacrolimus as baseline 
immunosuppression and secondly to further characterize his-
topathological changes associated with recovery from CR or 
progression to allograft failure. 
MATERIALS AND METHODS 
Case selection. Data retrieved from our in-house transplant clin-
ical information system, the Electronic Data Interface for Transplan-
tation (EDIT), showed that a total of 1049 adults received a first liver 
transplant between April 15. 1990 and June 30, 1994 at the Presby-
terian University Hospital, University of Pittsburgh Medical Center 
(UPMC). Patients must have survived for more than 14 days after 
surgery and had follow-up information available. The period during 
which transplantations were conducted is the same as that of the 
Liver Transplant Database (LTD) study on CR (19, 21), but patients 
in our study were followed for 3 years longer than the LTD cohort. 
Clinical and histological data were obtained from April 15, 1990 to 
September 1998. Baseline information included age, sex, race, which 
was recorded as Caucasian, black and other, MHC and blood types, 
primary disease of the recipient, and cold ischemia time. Preserva-
tion injury was assessed histologically. Ninety-eight (97.5) percent of 
patients received tacrolimus as baseline immunosuppression. and 
the remainder were treated with a cyclosporine-based regimen. Side 
effects warranted conversion from tacrolimus to cyclosporine in less 
than 5% of patients, whereas more than 50% of the patients who 
started on cyclosporine were switched to tacrolimus. Liver biopsies, 
cholangiograms, angiograms, and liver injury tests were performed 
when clinically indicated. After hospital discharge, clinical follow-up 
was conducted on patients twice a week for the first 6 weeks, once a 
week for 3 months, once every 2 weeks for 6 months, then monthly up 
to 1 year. Thereafter, contact was made every 6 weeks for 2 years, 
and then every 2 months thereafter, unless otherwise medically 
indicated. 
Of the 1049 patients, 112 had a primary or secondary histological 
diagnosis of CR on at least one biopsy specimen, using suboptimally 
defined criteria for CR. All biopsy specimens and explants with any 
diagnosis of CR, the biopsy specimen before the diagnosis of CR and, 
in case of resolution, the biopsy specimen upon which the resolution 
of CR was diagnosed, and the last available biopsy specimen, chol-
angiogram, ultrasound, and angiogram reports from these patients 
were reviewed. The objective was to determine whether the original 
diagnosis of CR was sustainable. 
More than four portal tracts were required to render a biopsy 
adequate. Bile duct pyknosis/atrophy, ductular reaction, arterial 
loss, obliterative arteriopathy, bridging necrosis, infarcts, and foam 
cell clusters were recorded as present or absent. Bile duct loss was 
calculated as the percentage of portal tracts without bile ducts. 
Portal and lobular inflammation, portal and central fibrosis and 
central lobular dropout were scored as none, mild, moderate, and 
severe. CR was defined as "early" in cases of atrophy/pyknosis in-
volving a majority of bile ducts but with less than 50% bile duct loss 
and as "late" when duct loss equaled or exceeded 50% or obliterative 
arteriopathy was seen. In addition, the presence of comorbid condi-
tions such as recurrent primary disease, biliary disease, ischemia. 
and acute cellular rejection (ACH) was recorded. 
After reviewing the histological evidence and clinical data, 77 
patients/grafts were excluded as bona fide examples of CR. The 
largest group of patients (n=41) was excluded because of insufficient 
histological evidence of CR. In most of these cases, CR was a second-
ary diagnosis and detected only on one sample. These were added to 
the no-CR group (Group 1). Fourteen patients were excluded because 
they had conditions that can be histologically indistinguishable from 
CR, namely biliary tract strictures (n=8) and hepatic artery stenosis 
or occlusion (n=6). In 22 cases, biopsy specimens were unavailable 
for review. The remaining 35 patients (Group 2) were analyzed in the 
first part of the study, which aimed to identify risk factors for the 
development of CR. Eighteen patients were analyzed for the second 
part of the study, which compared patients with graft failure due to 
CR and patients in whom CR resolved. Group 2A (n=8) consisted of 
patients in whom CR was the sole cause of graft failure. In group 
2 B (n=10), CR resolved either histologically or by normalization of 
liver injury tests. In seven patients, CR persisted, leading neither to 
resolution nor to graft failure by the end of the follow-up period 
(Group 2C). Ten patients with CR were excluded from the second 
part of the study because the graft failed or the patient died primar-
ily due to reasons other than CR (Group 2D): sepsis (n=6); gastro-
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intestinal hemorrhage (n=l); ruptured aortic aneurysm (n=l); mo-
tor vehicle accident (n = 1); and unknown (n = 1). 
Statistical analysis. Summary statistics are presented as the 
number and percentage for categorical data and as the median and 
range for continuous data. The Wilcoxon rank sum test was used for 
data that were ordinal or continuous, and chi-square tests were used 
for nominal data. Due to the small sample size, exact methods were 
used where appropriate. Proportional hazards models were fit to 
examine the relationship between age and CR after adjusting for 
preservation injury and number of acute rejection episodes. Time 
was defined as time to CR or to end offollow-up. P values less than 
0.05 indicate statistical significance. 
RESULTS 
Comparison of CR and non-CR groups. Thirty-five (group 
2) of 1049 patients (3.3%) developed CR; the remaining 1014 
patients comprised group 1. The median follow-up time was 
1973 days with a range from 16 to 3072 days. CR was first 
diagnosed between 16 and 2532 (median 242) days after 
transplantation with the incidence peaking early after trans-
plantation and decreasing with time (Fig. 1). Recipient age 
ranged from 18 to 77 years and did not differ between the two 
groups. No differences were found in recipient sex, race, and 
primary diagnoses, which were divided into nine groups (pri-
mary biliary cirrhosis, primary sclerosing cholangitis, auto-
immune hepatitis, viral hepatitis, alcohol abuse, malignancy, 
cryptogenic, metabolic, and other) (Table 1). Sixty-three (6%) 
of the patients initially received cyclosporine-based therapy 
in this study; there was no significant difference in the rate 
at which these patients developed CR. However, there was a 
significant crossover of cyclosporine-treated patients to ta-
crolimus. 
Donor age was significant when treated as a continuous 
variable. To further establish the approximate age at which 
this occurred, the data was plotted (Fig. 2), which resulted in 
a clustering of cases at 40-55 years. Thus, donor age was 
significantly higher in the group that developed CR (Table 1), 
and CR was associated with a donor age of more than 40 
years (P<0.04). This relationship was independent of the 
length of the intensive care unit stay of the donor, which was 
a median of 2 days in both age groups. In a proportional 
hazards regression analysis, which included donor age, pres-
DAYS TO CHRONIC REJECTION 
FIGURE 1. Time to the first histopathological diagnosis of Cft. 
TABLE 1. Demographic information and preservation injury 
in patients with and without CR 
Group 1 Group 2 
Variable 
(noCR) (CR) Pvalue 
n=1014 n=35 
Number(%) Number(%) 
Primary diagnosis 
PBC 91 (9) 4(11) NS 
PSC 78 (8) 4 (11) 
Metabolic 65 (6) 1(3) 
Viral hepatitis 259 (26) 9 (26) 
Neoplasm 67 (7) 1(3) 
Cryptogenic 133 (13) 5 (14) 
Autoimmune hepatitis 32 (3) 3 (7) 
Alcohol abuse 180 (18) 6 (17) 
Miscellaneous 98 (10) 2 (6) 
Missing 11 0 
Donor age 
<40 years 614 (61) 15 (43) 0.035 
>40 years 389 (39) 20 (57) 
Missing 11 
Preservation injury 
Yes 483 (48) 17 (49) NS 
No 531 (52) 18 (51) 
Abbreviations used in table: NS, not significant; PBC, primary 
biliary cirrhosis; PSC, primary sclerosing cholangitis. 
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FIGURE 2. Time to onset of CR by donor age. All of the sym-
bols represent cases of CRt and the outcome of the various 
cases are represented by the different symbols. (., graft 
failed or patient died, but not primarily because of CR; A, 
allograft failed because of CR; *, CR resolved as determined 
by liver injury tests and/or liver biopsy; +, patients with CR 
that neither resolved nor required retransplantation over 
the period of study) (see text). 
ervation injury, and number of ACR episodes, only donor age 
and number of ACR episodes remained independent risk 
factors for CR (data not shown). CR also occurred earlier in 
recipients of older organs (Fig. 2). There were no statistically 
significant differences in donor sex and race between the two 
groups. No differences could be detected in the length of cold 
ischemia time (analyzed continuously and as greater or less 
than 14 hr). Sex match and mismatch were analyzed accord-
ing to all possible combinations, and in addition, the combi-
nation of female recipient/male donor was tested against all 
other pairings. No differences could be'! detected between the 
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two groups (data not shown>. Similarly. there was no differ-
ence between the different race matches, even when the 
combinations white donor/white recipient and black donor/ 
white recipient and all donorslblack recipients were tested 
separately. The differences in ABO match and the number of 
HLA-A, B, A + B, and DR mismatches did not reach statistical 
significance. 
The number (P<O.OOl) and histopathological severity 
(P<0.005) of acute rejection episodes showed the strongest 
correlation with the development of CR (Table 2). However, 
whether the onset of acute rejection occurred within the first 
14 days was not significant. 
Outcome of CR. Based on clinical, histopathological, and 
biochemical criteria, patients with CR experienced one of 
four possible outcomes and were placed into the following 
groups (Fig. 2). Group 2A consisted of 8 patients who lost 
their grafts because of CR. In this group, time to CR ranged 
from 84 to 432 days with a median of 131 days, and graft 
failure occurred between 102 and 454 with a median of 268 
days. No patient in this group had recurrent primary disease. 
Group 2B consisted of 10 patients who recovered from CR 
to normal histology and liver function tests or to normal liver 
function tests. Seven of these patients also had biopsy-proven 
recovery. CR in this group was first diagnosed between 16 
and 981 (median 145) days after transplantation, and recov-
ery took place after 22 to 1285 (median 548) days. Two 
patients in this group also had recurrent disease (hepatitis 
B=l, hepatitis C=l). It should be emphasized that even 
though these patients eventually recovered, they experienced 
significant liver injury test elevations and histopathological 
changes on biopsy that merit inclusion under the diagnosis of 
early CR. These include marked elevations of the gamma-
glutamyl transpeptidase, alkaline phosphatase, and alanine 
aminotransferase (AL T), combined with bile duct atrophy 
affecting a majority of the bile ducts. Other stringent clinical 
and radiological selection criteria were also applied in an 
effort to exclude possible false-positive diagnoses of CR in 
patients with comorbid conditions that could produce a sim-
ilar clinicopathological profile. 
Group 2C consisted of seven patients with CR that neither 
TABLE 2. Timing, number of episodes, and maximum 
histopathologic severity of acute rejection episodes in 
patients with and without CR 
Variable 
First episode of ACR 
<14 days 
Yes 
No 
Number of episodes of 
ACR 
o 
1 
2 
3 
>4 
Maximum grade of ACR 
Mild 
Moderate 
Severe 
Group 1 
(noCR) 
n=1014 
Number (%) 
303 (55) 
250 (45) 
461 (45) 
406 (40) 
111 (11) 
27 (3) 
9(1) 
369 (67) 
160 (29) 
24 (4) 
Group 2 
(CR) 
n=35 
Number (%) 
14 (45) 
17 (55) 
4 (11) 
11 (31) 
11 (31) 
7 (20) 
2 (6) 
13 (42) 
15 (48) 
3 (10) 
P value 
NS 
<0.0001 
0.004 
led to graft failure nor to recovery until the end of the fol-
low-up period. In this group. CR occurred 68 to 2532 (median 
1406) days after transplantation and persisted for 340 to 
2116 days with a median 814 days. One patient also had 
recurrent primary biliary cirrhosis as a secondary diagnosis. 
Of the patients in group C, five had the changes of early CR 
and two patients had 82% and 69% bile duct loss, respec-
tively. Of the 10 other patients in group 2D who were ex-
cluded because of death (see Materials and Methods), only 
two had changes that could have contributed to significant 
allograft dysfunction, but it was determined not to be a 
significant contribution to the cause of death. 
Comparison of graft failure and resolution groups. No sta-
tistical differences could be found in the time to CR, cold 
ischemia time, recipient and donor age, race and sex, ABO 
match, and the number ofHLA-B and DR mismatches when 
comparing group 2A (failure) and group 2B (recovery) (data 
not shown). A higher number of HLA-A (P=0.08) and A + B 
mismatches (P=0.09) were of borderline significance for graft 
failure from CR. More patients in the recovery group had a 
cold ischemia time of more than 14 hr (P=0.09). There was 
an equal distribution of primary diagnoses between the two 
groups. Sex and race matches were analyzed in the same 
combinations as .in the analysis comparing patients who de-
veloped CR with those who did not and showed no statisti-
cally significant differences (data not shown). However, the 
race match/mismatch analysis was limited by the fact that all 
donors in both groups were Caucasian. 
No association with outcome was found in the number and 
severity of ACR episodes or whether the first episode oc-
curred before or after day 14 after transplantation (data not 
shown). However, maximum total bilirubin (P<0.02) and 
aspartate aminotransferase (AST) (P<0.03) were signifi-
cantly higher in the group that went on to graft failure (Table 
3). There was no difference in ALT and gamma-glutamyl 
transpeptidase between the groups. Alkaline phosphatase 
was also higher in group A (P=0.08). 
The features oflate CR were found significantly more often 
in patients whose grafts failed due to CR (Table 4). The 
maximum percentage of bile duct loss was higher in group A 
(P<O.Ol), and foam cell clusters were also more frequent in 
this group (P<O.Ol). However, only 38% ofthe patients who 
went on to graft failure showed bile duct loss involving more 
than 50% of portal tracts. The median percentage of bile duct 
loss in the graft failure group was 43%. No patient in group 
B had bile duct loss in more than 50% of portal tracts 
(P=0.07). Arterial loss occurred in 50% of patients in group 
2A but in no patients from group 2B (P<0.02). Severity of 
central fibrosis, when severe fibrosis was compared with all 
TABLE 3. Liver injury tests (highest value) during CR in 
patients witb CR leading to graft failure or recovery 
Group 2A Group 2B 
Variable (graft failure) (recovery) P value n=8 n=1O 
Median [range] Median [range] 
Total bilirubin 42.8 [3.9-51.7] 2.3 [0.5-7.4] 0.016 
AST 1574 [257-3598] 189 [27-673] 0.023 
ALT 648 [199-2359] 475 [38-990] NS 
Gamma-glutamyj 2133 [312-4681] 825 [26-61111 NS 
transpeptidase 
Alkaline phospbatase 2402 [45-3024] 251 [44-2209] 0.083 
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TABLE 4. Histological features of CR in patients going on to 
graft failure or recovery 
Group A Group B 
Variable (graft failure) (recovery) P value 
n=8 n=10 
Number(%) Number (%) 
Maximum % bile duct loss 
Median [range] 43 [0-100] 0[0-16] <0.01 
Maximum bile duct loss 
>50% 
Yes 3 (38) 0(0) 0.07 
No 5 (62) 10 (100) 
Arterial loss 
Yes 4 (50) 0(0) 0.02 
No 4 (50) 10 (100) 
Maximum severity of 
central fibrosis 
None, mild, moderate 7 (88) 10 (100) NS 
Severe 1 (12) 0(0) 
Foam cell clusters 
Yes 7 (88) 1 (10) <0.01 
No 1 (12) 9 (90) 
other grades, did not differ between the two groups. Only one 
patient whose graft failed due to CR had severe central 
fibrosis. Only one allograft from the graft failure group did 
not have obliterative arteriopathy on the liver allograft re-
moved at the time of retransplantation. However, this same 
failed allograft showed severe perivenular fibrosis, small ar-
terialloss, and bile duct loss in >50% of the portal tracts. 
DISCUSSION 
Similar to other organs, "immunological" factors most sig-
nificantly predisposed patients to the development of chronic 
liver allograft rejection. As in previous studies of liver allo-
grafts, the strongest correlation with the onset of CR was the 
frequency and severity of acute rejection episodes (12, 22, 23). 
However, in contrast to previous studies, there was no asso-
ciation between CR and MHC mismatches (24-26), male-to-
female mismatch or non-Caucasian recipient race (12, 27), or 
late onset acute rejection (12, 22, 28). Nor was CR more 
common in younger recipients (12, 19) or those with a pri-
mary diagnosis of autoimmune hepatitis (17, 29, 30). This 
suggests that tacrolimus more effectively controls the contri-
bution of mismatching and other immunological factors to 
CR and might also have a more potent early "tolerizing" 
effect in liver transplantation. 
This study also shows for the first time that the apparently 
nonimmunological factor of donor age >40 years contributed 
to the development ofCR in the liver. This is a well-described 
risk factor in kidney and heart allografts (31-33), but in liver 
allografts, older donor age has only been associated with 
delayed graft function (34) and a higher incidence of acute 
rejection (35). Although the mechanism is not known at this 
time, even the intrahepatic branches of the hepatic artery of 
older donors can be significantly affected by atherosclerosis 
(our unpublished observation) and, thus, may be more prone 
to the development of obliterative arteriopathy. 
Inadequate immunosuppression because of complicating 
infections, neoplasms. or noncompliance clearly influenced 
the rate of CR in this study, but it was difficult to quantify 
because drug levels were not systematically analyzed in the 
entire study population. However, detailed examination of 
the clinical histories of the 35 patients with CR revealed that 
18 (51%) of 35 either had infections or tumors or were non-
compliant and, thus, "inadequately" immunosuppressed. We 
suspect, but do not have proof, that noncompliance might 
also account for the third group of patients that developed CR 
late after transplantation. They tend to have younger donors 
and most show the early histological changes of CR and live 
with CR for several years, neither failing nor recovering. 
Alternatively, the different timing of onset of CR in this 
group may reflect a different immunological process than the 
other groups. This particular population illustrates that the 
threat of CR persists, even in long-surviving liver allograft 
recipients. 
Similar to the LTD study (19), serum AST, but not the 
ALT, and total bilirubin levels were significantly higher in 
those patients that ultimately required retransplantation. 
Since AST is the more liver-specific enzyme and mainly 
found in the mitochondria, it may be worthwhile to deter-
mine whether the mitochondrial fraction of the enzyme is 
elevated in the blood and whether mitochondria injury is an 
important cause of allograft dysfunction. 
Compared to the LTD study (19), CR in this tacrolimus-
treated population showed less bile duct injurylloss and less 
perivenular fibrosis. Of the patients requiring retransplan-
tation in the LTD study, the median bile duct loss was 100% 
and only one patient of 13 had bile duct loss ofless than 50%. 
In this study, although there was significantly more bile duct 
loss in patients who went on to graft failure, the median bile 
duct loss was only 43%. Perivenular fibrosis was more exten-
sive in failed allografts from both studies, but although se-
vere (central-to-central) bridging fibrosis was seen in most of 
the failed allografts in the LTD study, it was present in only 
one case from this study. Conversely, arterial loss was highly 
correlated with failure in the UPMC patients but only 
showed a trend in the LTD population (19). This finding 
further supports the theory that arterial damage in CR may 
be a stronger link to failure than bile duct loss, which may be 
reversible when the direct immunological attack is removed 
(12,20,36). The greater the potentially irreversible damage 
in the form of bile duct loss, obliterative arteriopathy, and 
perivenular fibrosis, the less likely the organ is to recover 
(Table 5). 
The slightly different expression of CR in the two studies 
may be a result of the different immunosuppressive regimens 
administered. In tissue culture, cyclosporine, but not tacroli-
mus, has been found to induce fibrogenesis by increasing 
TABLE 5. Histopathological features associated with early 
and late CR 
Atrophy in >50% of (remaining) bile ducts 
Bile duct loss in >50% of portal tracts 
Foam cell clusters 
Severe central fibrosis 
Arterial loss 
Severe arteriopathy 
CR 
Early Late 
+ 
-/+ 
-/+ 
+ 
+/-
+ 
+/-
+/-
+ 
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tumor growth factor-J3 production by small airway epithelial 
cells (37). Of the five different regimens in the LTD, three 
were cyclosporine based and only one contained tacrolimus, 
whereas UPMC patients were almost exclusively treated 
with tacrolimus. 
There are two aspects of chronic liver allograft rejection 
that are clearly different from other organs: the relatively 
low incidence, even when patients are followed over a long 
period of time; and the reversibility of the early stages. In 
kidney transplantation, hypertension, drug toxicity, and do-
nor-derived factors like atherosclerosis and accelerated se-
nescence (31) all contribute to the relentless and progressive 
decline of allograft function and structure that eventually 
plagues most renal allograft recipients (31, 38-40). In the 
liver, the opposite pattern is observed: after an initial peak 
during the first year after transplantation, the incidence 
declines steadily, but CR can still occur after a follow-up of up 
to 8 years, which was the cutoff for this study. This difference 
might be explained by the following. 
In contrast to clinical kidney or heart transplantation, 
experimental animal models of CR of these organs have been 
used to illustrate the point that the early stages of CR are 
"allo-antigen dependent" and reversible (41, 42). By retrans-
planting the kidney or heart allograft with the early stages of 
CR back into syngeneic recipients, the alloantigenic stimu-
lus/injury is removed and the organ recovers. Extrapolation 
of this line of reasoning to human liver allograft recipients 
would suggest that resolution of CR very well might repre-
sent resolution of the immunological or alloantigen depen-
dent factors and a greater tolerance of the allograft, as sug-
gested nearly four decades ago (43). Theoretically, this could 
occur via activation-induced clonal deletion (4, 43, 44), aug-
mentation of regulatory pathways (45), liver injury-induced 
augmentation of donor microchimerism (46), or most likely, a 
combination of the above. 
In addition, architecturally correct repair of the damage 
already incurred would be much easier in the liver than in 
the kidney, because of the constraints imposed by the rigidity 
and complexity of organ structure, as well as the regenera-
tive capacity of the epithelial cell populations. Even adult 
hepatocytes are thought to have an almost unlimited poten-
tial to regenerate (47), and injured or destroyed bile duct cells 
are able to reconstitute as well (11, 12, 19). Thus, it is not 
unreasonable to suggest that augmentation of epithelial re-
generation during acute rejection damage in the kidney us-
ing growth factors might delay or prevent some of the archi-
tectural decline seen during the development of chronic 
allograft nephropathy. 
In summary, better recognition and control of the acute 
and the early stage of CR has minimized the impact of CR on 
liver allograft recipients. However, the threat of CR still 
exists in long-term liver allograft recipients, and thus con-
tinues to be an important cause of allograft dysfunction (1, 
17). Potentially irreversible damage to structures targeted in 
rejection, the bile ducts, arteries and veins, can be used along 
with clinical and laboratory data to stage CR and assist 
clinical management. The changing risk factors and the 
unique immunological and regenerative properties of a liver 
allograft, such as the low incidence and reversibility of early 
CR, will likely continue to provide insights into transplanta-
tion immunobiology. 
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